Zwipe appoints APAC Head to strengthen its regional presence
OSLO, NORWAY and SINGAPORE - Media OutReach - 11 November 2021 - Zwipe, a leading biometrics payment company, announced…
4 years ago
Samsung Announces Availability of Its Leading-Edge 2.5D Integration ‘H-Cube’ Solution for High Performance Applications
'H-Cube' applies advanced silicon interposer technology and hybrid-substrate structure, allowing efficient integration of 6 HBMs,…
4 years ago
GEODIS wins ‘Best Logistics Service Provider – Project Cargo’ at the 2021 AFLAS Awards
Sustained innovation and high service quality place GEODIS at the very top of the Best…
4 years ago
CUHK Business School Research Finds Rural Migrants in China Are Likely to Establish Bigger Companies
HONG KONG SAR - Media OutReach - 11 November 2021 - Big cities are where dreams thrive. Their…
4 years ago
VisualCamp Eye Tracking Software, SeeSo Named as CES 2022 Innovation Awards Honoree
SEOUL, South Korea--(BUSINESS WIRE)--#AIBasedEyeTrackingSolution--VisualCamp announced that it has been named a CES® 2022 Innovation Awards…
4 years ago
Coupang Reschedules Third Quarter 2021 Results to November 12, 2021
SEOUL, South Korea--(BUSINESS WIRE)--In recognition of the U.S. Federal Holiday, Coupang, Inc. (NYSE: CPNG) is…
4 years ago
Asia Pacific Sourcing Market Driven by Cloud Services in Q3
IaaS and SaaS demand continues to climb to record highs, but managed services growth slows…
4 years ago
Johnson Electric & Cortica Establish New Joint Venture Lean AI to Bring Revolutionary Quality Inspection to Manufacturing
Automating quality assurance in manufacturing through Autonomous AI will drive flawless quality and production while…
4 years ago
Dreamstime’s Android Companion for Contributors Now Connects With Instagram and Google Photos
NASHVILLE, Tenn.--(BUSINESS WIRE)--#ThePhotoHour--Dreamstime, the world’s largest stock photo community, announces it has optimized its contributors’…
4 years ago
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
-- The EVER-132-001 trial met its primary endpoint with an objective response rate of 38.8%…
4 years ago